Entasis Therapeutics Awarded Contract from National Institutes of Health
July 06 2020 - 8:00AM
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage
biopharmaceutical company focused on the discovery and development
of novel antibacterial products, today announced it has entered
into a contract with the National Institute of Allergy and
Infectious Diseases (NIAID), part of the National Institutes of
Health (NIH). The initial award of approximately $3 million, with
the potential to increase up to $15.5 million, will be used to
develop novel molecules from its non-β-lactam inhibitor (NBP)
platform with expanded antimicrobial spectrum.
“We are extremely pleased that NIAID has awarded
Entasis this contract that will help further expand the scope of
our NBP program,” commented Dr. Ruben Tommasi, Chief Scientific
Officer of Entasis Therapeutics. “This funding validates the
pre-clinical safety and efficacy data demonstrated by our lead NBP
candidate, ETX0462, in both in vivo and in vitro models against
drug-resistant Pseudomonas aeruginosa infections, and the potential
of the NBP platform to deliver additional molecules with expanded
antimicrobial spectrum. We look forward to pursuing development of
additional candidates from this novel class of Gram-negative
antibiotics.”
Funding from the contract will support research
towards developing molecules with expanded Gram-negative spectrum
against antibiotic resistant bacterial pathogens including E. coli,
Acinetobacter, Pseudomonas and Klebsiella. Subject to achieving
pre-defined milestones, the contract will fund work up to IND-ready
stage. National Institutes of Health, National Institute of Allergy
and Infectious Diseases contract 75N93020C00017.
About EntasisEntasis is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of novel antibacterial products
to treat serious infections caused by multidrug-resistant
Gram-negative bacteria. Entasis’ pathogen-targeted design platform
has produced a pipeline of product candidates, including
sulbactam-durlobactam (targeting Acinetobacter baumannii
infections), zoliflodacin (targeting Neisseria gonorrhoeae
infections), ETX0282CPDP (targeting Enterobacteriaceae infections)
and ETX0462 (targeting Pseudomonas infections). For more
information, visit www.entasistx.com.
Entasis Forward-looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,”
“anticipate,” “estimate,” “intend” and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. These forward-looking statements are based on Entasis’
expectations and assumptions as of the date of this press release.
Each of these forward-looking statements involves risks and
uncertainties. Actual results may differ materially from these
forward-looking statements. Many factors may cause differences
between current expectations and actual results, including
unexpected safety or efficacy data observed during non-clinical or
clinical studies, clinical site activation rates or clinical trial
enrollment rates that are lower than expected and changes in
expected or existing competition, changes in the regulatory
environment, failure of Entasis’ collaborators to support or
advance collaborations or product candidates and unexpected
litigation or other disputes. Many of these factors are beyond
Entasis’ control. These and other risks and uncertainties are
described more fully in the Entasis’ filings with the U.S.
Securities and Exchange Commission, including the section titled
“Risk Factors” contained therein. Forward-looking statements
contained in this announcement are made as of this date, and except
as required by law, Entasis assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
Entasis Company Contact
Kyle Dow Entasis Therapeutics (781)
810-0114 kyle.dow@entasistx.com
Investor Relations Contacts Tram Bui / James
Salierno The Ruth Group (646) 536-7035 / 7028 tbui@theruthgroup.com
jsalierno@theruthgroup.com
Media ContactKirsten ThomasThe Ruth Group(508)
280-6592kthomas@theruthgroup.com
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Sep 2023 to Sep 2024